Platelet-Rich Plasma Promotes the Proliferation of Human Muscle Derived Progenitor Cells and Maintains Their Stemness

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Li, Hongshuai ^a   Usas, Arvydas ^a   Poddar, Minakshi ^a   Chen, Chien Wen ^a   Thompson, Seth ^a   Ahani, Bahar ^a   Cummins, James ^a   Lavasani, Mitra ^a   Huard, Johnny ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARTILAGE CELL; CELL ISOLATION; CELL POPULATION; CELL PROLIFERATION; CHONDROGENESIS; CONTROLLED STUDY; ENDOTHELIUM CELL; EX VIVO STUDY; FLUORESCENCE ACTIVATED CELL SORTING; GASTROCNEMIUS MUSCLE; HUMAN; HUMAN CELL; HUMAN MUSCLE DERIVED PROGENITOR CELL; HUMAN TISSUE; IN VIVO STUDY; MALE; MITOGENESIS; MOUSE; MUSCLE INJURY; MUSCLE REGENERATION; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOBLAST; PERICYTE; PROTEIN EXPRESSION; STEM CELL; STEM CELL EXPANSION; THROMBOCYTE RICH PLASMA;

AGED; ANIMALS; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CELL PROLIFERATION; FLOW CYTOMETRY; HUMANS; MALE; MICE; MICE, SCID; MIDDLE AGED; MITOGENS; MUSCLE CELLS; MUSCLE DEVELOPMENT; PLATELET-DERIVED GROWTH FACTOR; PLATELET-RICH PLASMA; STEM CELLS;

ANIMALIA;

EID: 84878753657     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064923     Document Type: Article

References (79)

1. Deasy BM, Jankowski RJ, Huard J, (2001) Muscle-derived stem cells: characterization and potential for cell-mediated therapy. Blood Cells Mol Dis 27: 924-933.
2. Mastrogiacomo M, Derubeis AR, Cancedda R, (2005) Bone and cartilage formation by skeletal muscle derived cells. J Cell Physiol 204: 594-603.
3. Levy MM, Joyner CJ, Virdi AS, Reed A, Triffitt JT, et al. (2001) Osteoprogenitor cells of mature human skeletal muscle tissue: an in vitro study. Bone 29: 317-322.
4. Oshima H, Payne TR, Urish KL, Sakai T, Ling Y, et al. (2005) Differential myocardial infarct repair with muscle stem cells compared to myoblasts. Mol Ther 12: 1130-1141.
5. Qu-Petersen Z, Deasy B, Jankowski R, Ikezawa M, Cummins J, et al. (2002) Identification of a novel population of muscle stem cells in mice: potential for muscle regeneration. J Cell Biol 157: 851-864.
6. Matsumoto T, Cooper GM, Gharaibeh B, Meszaros LB, Li G, et al. (2009) Cartilage repair in a rat model of osteoarthritis through intraarticular transplantation of muscle-derived stem cells expressing bone morphogenetic protein 4 and soluble Flt-1. Arthritis Rheum 60: 1390-1405.
7. Gates CB, Karthikeyan T, Fu F, Huard J, (2008) Regenerative medicine for the musculoskeletal system based on muscle-derived stem cells. J Am Acad Orthop Surg 16: 68-76.
8. Cao B, Huard J, (2004) Muscle-derived stem cells. Cell Cycle 3: 104-107.
9. Urish KL, Vella JB, Okada M, Deasy BM, Tobita K, et al. (2009) Antioxidant levels represent a major determinant in the regenerative capacity of muscle stem cells. Mol Biol Cell 20: 509-520.
10. Peault B, Rudnicki M, Torrente Y, Cossu G, Tremblay JP, et al. (2007) Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. Mol Ther 15: 867-877.
11. Mauro A, (1961) Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol 9: 493-495.
12. Zheng B, Cao B, Crisan M, Sun B, Li G, et al. (2007) Prospective identification of myogenic endothelial cells in human skeletal muscle. Nat Biotechnol 25: 1025-1034.
13. Shepro D, Morel NM, (1993) Pericyte physiology. FASEB J 7: 1031-1038.
14. Dellavalle A, Sampaolesi M, Tonlorenzi R, Tagliafico E, Sacchetti B, et al. (2007) Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nat Cell Biol 9: 255-267.
15. Covas DT, Panepucci RA, Fontes AM, Silva WA Jr, Orellana MD, et al. (2008) Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146+ perivascular cells and fibroblasts. Exp Hematol 36: 642-654.
16. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, et al. (2008) A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3: 301-313.
17. Kievits F, Boerenkamp WJ, Ivanyi P, (1988) H-2-dependent binding of xenogeneic beta 2-microglobulin from culture media. J Immunol 140: 4253-4255.
18. MacDermott RP, Bragdon MJ (1983) Fetal calf serum augmentation during cell separation procedures accounts for the majority of human autologous mixed leukocyte reactivity. Behring Inst Mitt: 122-128.
19. Nguyen RT, Borg-Stein J, McInnis K, (2011) Applications of platelet-rich plasma in musculoskeletal and sports medicine: an evidence-based approach. PM R 3: 226-250.
20. Lee KS, Wilson JJ, Rabago DP, Baer GS, Jacobson JA, et al. (2011) Musculoskeletal applications of platelet-rich plasma: fad or future? AJR Am J Roentgenol 196: 628-636.
21. Soomekh DJ, (2011) Current concepts for the use of platelet-rich plasma in the foot and ankle. Clin Podiatr Med Surg 28: 155-170.
22. Borrione P, Gianfrancesco AD, Pereira MT, Pigozzi F, (2010) Platelet-rich plasma in muscle healing. Am J Phys Med Rehabil 89: 854-861.
23. Alsousou J, Thompson M, Hulley P, Noble A, Willett K, (2009) The biology of platelet-rich plasma and its application in trauma and orthopaedic surgery: a review of the literature. J Bone Joint Surg Br 91: 987-996.
24. Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, et al. (1998) Platelet-rich plasma: Growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 85: 638-646.
25. Shahdadfar A, Fronsdal K, Haug T, Reinholt FP, Brinchmann JE, (2005) In vitro expansion of human mesenchymal stem cells: choice of serum is a determinant of cell proliferation, differentiation, gene expression, and transcriptome stability. Stem Cells 23: 1357-1366.
26. Lange C, Cakiroglu F, Spiess AN, Cappallo-Obermann H, Dierlamm J, et al. (2007) Accelerated and safe expansion of human mesenchymal stromal cells in animal serum-free medium for transplantation and regenerative medicine. J Cell Physiol 213: 18-26.
27. Kasten P, Vogel J, Luginbuhl R, Niemeyer P, Weiss S, et al. (2006) Influence of platelet-rich plasma on osteogenic differentiation of mesenchymal stem cells and ectopic bone formation in calcium phosphate ceramics. Cells Tissues Organs 183: 68-79.
28. Niemeyer P, Fechner K, Milz S, Richter W, Suedkamp NP, et al. (2010) Comparison of mesenchymal stem cells from bone marrow and adipose tissue for bone regeneration in a critical size defect of the sheep tibia and the influence of platelet-rich plasma. Biomaterials 31: 3572-3579.
29. Bieback K, Hecker A, Kocaomer A, Lannert H, Schallmoser K, et al. (2009) Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells 27: 2331-2341.
30. Doucet C, Ernou I, Zhang Y, Llense JR, Begot L, et al. (2005) Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol 205: 228-236.
31. Kocaoemer A, Kern S, Kluter H, Bieback K, (2007) Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells 25: 1270-1278.
32. Qu Z, Balkir L, van Deutekom JC, Robbins PD, Pruchnic R, et al. (1998) Development of approaches to improve cell survival in myoblast transfer therapy. J Cell Biol 142: 1257-1267.
33. Rando TA, Blau HM, (1994) Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. J Cell Biol 125: 1275-1287.
34. Musgrave DS, Pruchnic R, Bosch P, Ziran BH, Whalen J, et al. (2002) Human skeletal muscle cells in ex vivo gene therapy to deliver bone morphogenetic protein-2. J Bone Joint Surg Br 84: 120-127.
35. Lee JY, Peng H, Usas A, Musgrave D, Cummins J, et al. (2002) Enhancement of bone healing based on ex vivo gene therapy using human muscle-derived cells expressing bone morphogenetic protein 2. Hum Gene Ther 13: 1201-1211.
36. Bieback K, Kern S, Kluter H, Eichler H, (2004) Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 22: 625-634.
37. Petrenko O, Beavis A, Klaine M, Kittappa R, Godin I, et al. (1999) The molecular characterization of the fetal stem cell marker AA4. Immunity 10: 691-700.
38. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315-317.
39. Zong M, Lundberg IE, (2011) Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol 7: 297-306.
40. Garbayo E, Raval AP, Curtis KM, Della-Morte D, Gomez LA, et al. (2011) Neuroprotective properties of marrow-isolated adult multilineage-inducible cells in rat hippocampus following global cerebral ischemia are enhanced when complexed to biomimetic microcarriers. J Neurochem 119: 972-988.
41. Dohan Ehrenfest DM, Rasmusson L, Albrektsson T, (2009) Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol 27: 158-167.
42. Kalen A, Wahlstrom O, Linder CH, Magnusson P, (2008) The content of bone morphogenetic proteins in platelets varies greatly between different platelet donors. Biochem Biophys Res Commun 375: 261-264.
43. Weibrich G, Kleis WK, Hafner G, Hitzler WE, (2002) Growth factor levels in platelet-rich plasma and correlations with donor age, sex, and platelet count. J Craniomaxillofac Surg 30: 97-102.
44. Mazzucco L, Balbo V, Cattana E, Guaschino R, Borzini P, (2009) Not every PRP-gel is born equal. Evaluation of growth factor availability for tissues through four PRP-gel preparations: Fibrinet, RegenPRP-Kit, Plateltex and one manual procedure. Vox Sang 97: 110-118.
45. Lei H, Gui L, Xiao R, (2009) The effect of anticoagulants on the quality and biological efficacy of platelet-rich plasma. Clin Biochem 42: 1452-1460.
46. Mishra A, Harmon K, Woodall J, Vieira A (2011) Sports Medicine Applications of Platelet Rich Plasma. Curr Pharm Biotechnol.
47. Gassling VL, Acil Y, Springer IN, Hubert N, Wiltfang J, (2009) Platelet-rich plasma and platelet-rich fibrin in human cell culture. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 108: 48-55.
48. Martin JF, Plumb J, Kilbey RS, Kishk YT, (1983) Changes in volume and density of platelets in myocardial infarction. Br Med J (Clin Res Ed) 287: 456-459.
49. Mathur A, Robinson MS, Cotton J, Martin JF, Erusalimsky JD, (2001) Platelet reactivity in acute coronary syndromes: evidence for differences in platelet behaviour between unstable angina and myocardial infarction. Thromb Haemost 85: 989-994.
50. Tschoepe D, Roesen P, Esser J, Schwippert B, Nieuwenhuis HK, et al. (1991) Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost 17: 433-438.
51. Scharf RE, Rahman MM, Seidel H, (2011) The impact and management of acquired platelet dysfunction. Hamostaseologie 31: 28-40.
52. Refaai MA, Phipps RP, Spinelli SL, Blumberg N, (2011) Platelet transfusions: impact on hemostasis, thrombosis, inflammation and clinical outcomes. Thromb Res 127: 287-291.
53. Lubowitz JH, Provencher MT, Poehling GG, (2011) Two steps forward, one step back. Arthroscopy 27: 1453-1455.
54. Gruber R, Karreth F, Kandler B, Fuerst G, Rot A, et al. (2004) Platelet-released supernatants increase migration and proliferation, and decrease osteogenic differentiation of bone marrow-derived mesenchymal progenitor cells under in vitro conditions. Platelets 15: 29-35.
55. Lucarelli E, Beccheroni A, Donati D, Sangiorgi L, Cenacchi A, et al. (2003) Platelet-derived growth factors enhance proliferation of human stromal stem cells. Biomaterials 24: 3095-3100.
56. Vogel JP, Szalay K, Geiger F, Kramer M, Richter W, et al. (2006) Platelet-rich plasma improves expansion of human mesenchymal stem cells and retains differentiation capacity and in vivo bone formation in calcium phosphate ceramics. Platelets 17: 462-469.
57. Parsons P, Butcher A, Hesselden K, Ellis K, Maughan J, et al. (2008) Platelet-rich concentrate supports human mesenchymal stem cell proliferation, bone morphogenetic protein-2 messenger RNA expression, alkaline phosphatase activity, and bone formation in vitro: a mode of action to enhance bone repair. J Orthop Trauma 22: 595-604.
58. Zaky SH, Ottonello A, Strada P, Cancedda R, Mastrogiacomo M, (2008) Platelet lysate favours in vitro expansion of human bone marrow stromal cells for bone and cartilage engineering. J Tissue Eng Regen Med 2: 472-481.
59. Rosner MH, Vigano MA, Ozato K, Timmons PM, Poirier F, et al. (1990) A POU-domain transcription factor in early stem cells and germ cells of the mammalian embryo. Nature 345: 686-692.
60. Niwa H, Miyazaki J, Smith AG, (2000) Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 24: 372-376.
61. Pesce M, Scholer HR, (2001) Oct-4: gatekeeper in the beginnings of mammalian development. Stem Cells 19: 271-278.
62. Chambers I, Colby D, Robertson M, Nichols J, Lee S, et al. (2003) Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 113: 643-655.
63. Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, et al. (2003) The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 113: 631-642.
64. Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK, et al. (2005) Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 26: 495-502.
65. Pierantozzi E, Gava B, Manini I, Roviello F, Marotta G, et al. (2011) Pluripotency regulators in human mesenchymal stem cells: expression of NANOG but not of OCT-4 and SOX-2. Stem Cells Dev 20: 915-923.
66. Kashyap V, Rezende NC, Scotland KB, Shaffer SM, Persson JL, et al. (2009) Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs. Stem Cells Dev 18: 1093-1108.
67. Riekstina U, Cakstina I, Parfejevs V, Hoogduijn M, Jankovskis G, et al. (2009) Embryonic stem cell marker expression pattern in human mesenchymal stem cells derived from bone marrow, adipose tissue, heart and dermis. Stem Cell Rev 5: 378-386.
68. Olson EN, (1992) Proto-oncogenes in the regulatory circuit for myogenesis. Semin Cell Biol 3: 127-136.
69. Risau W, Drexler H, Mironov V, Smits A, Siegbahn A, et al. (1992) Platelet-derived growth factor is angiogenic in vivo. Growth Factors 7: 261-266.
70. Fiedler J, Roderer G, Gunther KP, Brenner RE, (2002) BMP-2, BMP-4, and PDGF-bb stimulate chemotactic migration of primary human mesenchymal progenitor cells. J Cell Biochem 87: 305-312.
71. Cassiede P, Dennis JE, Ma F, Caplan AI, (1996) Osteochondrogenic potential of marrow mesenchymal progenitor cells exposed to TGF-beta 1 or PDGF-BB as assayed in vivo and in vitro. J Bone Miner Res 11: 1264-1273.
72. Park JS, Chu JS, Tsou AD, Diop R, Tang Z, et al. (2011) The effect of matrix stiffness on the differentiation of mesenchymal stem cells in response to TGF-beta. Biomaterials 32: 3921-3930.
73. Zhou S, (2011) TGF-beta regulates beta-catenin signaling and osteoblast differentiation in human mesenchymal stem cells. J Cell Biochem 112: 1651-1660.
74. Huang Z, Ren PG, Ma T, Smith RL, Goodman SB, (2010) Modulating osteogenesis of mesenchymal stem cells by modifying growth factor availability. Cytokine 51: 305-310.
75. Linkhart TA, Mohan S, Baylink DJ, (1996) Growth factors for bone growth and repair: IGF, TGF beta and BMP. Bone 19: 1S-12S.
76. Chen L, Jiang W, Huang J, He BC, Zuo GW, et al. (2010) Insulin-like growth factor 2 (IGF-2) potentiates BMP-9-induced osteogenic differentiation and bone formation. J Bone Miner Res 25: 2447-2459.
77. Guo J, Lin G, Bao C, Hu Z, Chu H, et al. (2008) Insulin-like growth factor 1 improves the efficacy of mesenchymal stem cells transplantation in a rat model of myocardial infarction. J Biomed Sci 15: 89-97.
78. Tamama K, Fan VH, Griffith LG, Blair HC, Wells A, (2006) Epidermal growth factor as a candidate for ex vivo expansion of bone marrow-derived mesenchymal stem cells. Stem Cells 24: 686-695.
79. Tamama K, Kawasaki H, Wells A, (2010) Epidermal growth factor (EGF) treatment on multipotential stromal cells (MSCs). Possible enhancement of therapeutic potential of MSC. J Biomed Biotechnol 2010: 795385.